The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The efficacy of hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: A phase 3 randomized self-controlled study, J-SUPPORT 1701 APRON trial.
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Asako Ryu
No Relationships to Disclose
 
Sadamoto Zenda
Honoraria - Bristol-Myers Squibb Japan; Maruho; Merck; Ono Yakuhin
 
Michiko Arai
No Relationships to Disclose
 
Yusuke Takagi
No Relationships to Disclose
 
Tempei Miyaji
No Relationships to Disclose
 
Tomoe Mashiko
No Relationships to Disclose
 
Yoichi Shimizu
No Relationships to Disclose
 
Arata Tsutsumida
No Relationships to Disclose
 
Akira Takahashi
No Relationships to Disclose
 
Naoya Yamazaki
Consulting or Advisory Role - Incyte; Maruho; Ono Pharmaceutical; Otsuka
Speakers' Bureau - Bristol-Myers Squibb Japan; Maruho; MSD; Novartis; Ono Pharmaceutical; Sun Pharma
Research Funding - Astellas Amgen BioPharama (Inst); Bristol-Myers Squibb Japan (Inst); GlaxoSmithKline; Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Takara Bio (Inst)
 
Chigusa Morizane
Honoraria - Eisai; MSD K.K.; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - MSD K.K.; SERVIER; Yakult Honsha
Research Funding - AstraZeneca (Inst); Daiichi Sankyo RD Novare; Eisai (Inst); Hitachi (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - 3H Clinical Trial; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED.; Eisai; EP Croit Co.; Incyte; Japan Tobacco Inc; Kowa; Ono Pharmaceutical; Otsuka; Seikagaku; Sonire Therapeutics
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Mebix; Takeda
Research Funding - 3H Clinical Trial (Inst); 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); ClinChoice (Inst); Eisai (Inst); Facet Biotech (Inst); Hemp Kitchen (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Kyowa Kirin Co., Ltd.; Medidata Solutions, Inc (Inst); Medrio (Inst); NIPRO CORPORATION (Inst); Nobori Ltd. (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Puravida Technologies (Inst); Senju Pharmaceutical (Inst); Welby (Inst)
 
Takashi Kawaguchi
No Relationships to Disclose
 
Yosuke Uchitomi
No Relationships to Disclose